triptorelin

(redirected from Decapeptyl)
Also found in: Wikipedia.

triptorelin

 [trip″to-rel´in]
a synthetic analogue of gonadorelin that on prolonged administration suppresses gonadotropin release; used as triptorelin pamoate as an antineoplastic in the palliative treatment of prostatic carcinoma, administered intramuscularly.

triptorelin

/trip·to·rel·in/ (trip″to-rel´in) a synthetic gonadorelin analogue that on prolonged administration suppresses gonadotropin release; used as t. pamoate as an antineoplastic in the treatment of prostatic carcinoma.

triptorelin

a gonadotropin-releasing hormone used to treat advanced prostate cancer.

triptorelin

Therapeutics A long-acting gonadotropin-releasing hormone analogue, that induces intense reversible hypogonadism by inhibiting LH and, to a lesser degree, FSH release, resulting in ↓ testosterone Indications Advanced prostate and ovarian CA; it may have a role in Rx-refractory sexual deviancy. See Paraphilia.

triptorelin

A synthetic gonadotrophin-releasing hormone used to treat advances cancer of the PROSTATE GLAND. A brand name is Decapeptyl SR.
References in periodicals archive ?
The 1- and 3-month formulations have already been registered in numerous countries and are available under different brand names: Trelstar, Decapeptyl and Pamorelin.
If Decapeptyl is used, the cost of one injection will make 1,966 som.
Decapeptyl, Taxotere, Jevtana and Provenge are the other popular prostate cancer drugs in the global market.
Hexvix will develop commercial synergies with Decapeptyl, our GnRh analog indicated for the treatment of advanced prostate cancer and with tasquinimod currently in phase III development by our partner Active Biotech for asymptomatic or mildly symptomatic, chemotherapy-naive men with metastatic, castration-resistant prostate cancer (mCRPC).
The 1- and 3-month-formulations have been registered in most countries and are currently available under the names of Trelstar in North America, Decapeptyl /Pamorelin in Europe and Latin America and from now on, of Pamorelin in India.
16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 81
Figure 48: Prostate Cancer, US, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 90
Figure 42: Prostate Cancer, Spain, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 82
Figure 42: Prostate Cancer, Japan, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 79
Figure 42: Prostate Cancer, France, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 80
Figure 42: Prostate Cancer, Germany, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 76